SEARCH

SEARCH BY CITATION

References

  • 1
    Kramer H, Molitch ME. Screening for kidney disease in adults with diabetes. Diabetes Care 2005; 28: 18131816.
  • 2
    Flynn C, Bakris G. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol 2013; 9: 147153.
  • 3
    Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 2007; 25: 9097.
  • 4
    Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 13641379.
  • 5
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 6
    Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 63556360.
  • 7
    Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669672.
  • 8
    Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555.
  • 9
    Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539545.
  • 10
    Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 12321238.
  • 11
    Polidori D, Sakai M, Devineni D. Exposure-response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM) (Abstract 1072-P). Diabetes 2011; 60(Suppl. 1): A294.
  • 12
    Levey AS, Coresh J, Greene T et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766772.
  • 13
    National Kidney Foundation. Kidney disease outcomes quality initiative. clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. 2002.
  • 14
    Niskanen L, Cefalu WT, Leiter LA et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin (Abstract 763). Diabetologia 2012; 55(Suppl. 1): S314.
  • 15
    Schernthaner G, Gross J, Fu M et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulphonylurea (Abstract 243). Diabetologia 2012; 55(Suppl. 1): S108.
  • 16
    Stenlof K, Cefalu WT, Tong C et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemic control in subjects with type 2 diabetes inadequately controlled with diet and exercise (Abstract 760). Diabetologia 2012; 55(Suppl. 1): S312313.
  • 17
    Wilding J, Mathieu C, Deng L et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea (Abstract 766). Diabetologia 2012; 55(Suppl. 1): S315316.
  • 18
    Devineni D, Marbury TC, Curtin CR et al. Effects of renal function on canagliflozin (CANA) pharmacokinetics (PK) and pharmacodynamics (PD) in non-diabetic subjects (Abstract PUB295). J Am Soc Nephrol 2012; 23: 961A.
  • 19
    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 26282635.
  • 20
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733745.
  • 21
    Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 10831091.
  • 22
    Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928938.
  • 23
    Wilding JP, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405415.
  • 24
    de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 23092320.
  • 25
    The National Kidney Disease Education Program (NKDEP). Urine albumin-to-creatinine ratio (UACR) in evaluating patients with diabetes for kidney disease. 2010.
  • 26
    Kohan DE, Fioretto P, List J, Tang W. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (Abstract TH-PO524). J Am Soc Nephrol 2011; 22(Suppl): 232-A.